SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
April 28, 2010
Date of Report (Date of earliest event reported)
BIONOVO, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| | |
| 001-33498 | | 20-5526892 |
| (Commission File Number) | | (IRS Employer Identification No.) |
5858 Horton Street, Suite 400, Emeryville, CA 94608
(Address of Principal Executive Office) (Zip Code)
(510) 601-2000
(Registrant's Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On April 28, 2010, Bionovo, Inc. (the Company) released via press release the Annual Letter to Shareholders, which is available on the Company’s website, www.bionovo.com.
The Annual Letter to Shareholders may contain statements of a forward-looking nature relating to future events. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| | |
| (d) | | Exhibits. |
| |
| 99.1 | | Press release from Bionovo, Inc., dated April 28, 2010, entitled “Bionovo to Hold Annual Shareholder Meeting May 3, 2010” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | BIONOVO, INC |
| | | | (Registrant) |
| | | |
| Date: April 28, 2010 | | | | By: | | /s/ ISAAC COHEN |
| | | | | | Isaac Cohen Chairman and Chief Executive Officer (Principal Executive Officer) |
EXHIBIT INDEX
| | |
| EXHIBIT 99.1 | | Press release from Bionovo, Inc., dated April 28, 2010, entitled “Bionovo to Hold Annual Shareholder Meeting May 3, 2010” |
